These data were derived from Gene Expression Omnibus data set GSE67784. “Early diagnosis of transthyretin (TTR) amyloid diseases remains challenging because of variable disease penetrance. Currently, patients must have an amyloid positive tissue biopsy to be eligible for disease modifying therapies.”
Comment(s): This data set was curated as part of the Biomarker Benchmark project. The expression data were normalized using the SCAN algorithm and summarized at the gene level using Ensembl identifiers.
Data Source(s): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67784
Citation(s): PubMed article